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Abstract 
This article introduces a strategy for stabilizing and redispersing layered double hydroxide 
(LDH) nanoparticles by crosslinking bovine serum albumin (BSA) coated onto the surface. 
The strategy involves optimization of the amount of the crosslinking agent glutaraldehyde 
(GTA) to achieve minimal aggregation and ready redispersion. LDH nanoparticles were 
prepared by co-precipitation and hydrothermal treatment, with subsequent bovine serum 
albumin (BSA) coating at the BSA/LDH mass ratio of 5:2. BSA coated onto LDH 
nanoparticles was crosslinked with different amounts of GTA. Aggregation studies using 
dilution assays, dynamic light scattering, and zeta potential analysis indicated that severe 
aggregation at lower LDH nanoparticle concentrations can be prevented by proper 
crosslinking of BSA with GTA. The GTA-crosslinked BSA-coated nanoparticles showed 
excellent redispersity compared to the non-crosslinked nanoparticles. In vitro cytotoxicity 
and cell uptake were found to be minimally affected by GTA-crosslinking. The new strategy 
therefore provides a much more effective method for the prevention of LDH nanoparticle 
aggregation and improved LDH nanoparticle redispersion for use in a wide variety of bio-
applications in vitro and in vivo. 
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1. Introduction 
Due to their potential application in biomedical therapeutics, nanoparticles have attracted 
intense scientific interest. Nanoparticles normally have at least one dimension in the range of 
1-100 nm, and can therefore readily enter the cell microenvironment.
[1, 2] 
Stabilization of 
nanoparticles is a fundamental requirement necessary for successful use in clinical 
applications. Upon intravenous injection, nanoparticles often interact with biological 
environments that consist of biomolecules such as proteins, sugars, and electrolytes. These 
interactions can lead to nanoparticle aggregation and blockage of blood vessels and 
capillaries. Therefore, it is of particular importance that nanoparticles avoid aggregation in 
the in vivo situation.
[3-5]
 The development of nanotechnology allows researchers to rationally 
engineer nanoparticles for targeted delivery, prolonged circulation half-life, improved 
therapeutic index and reduced immunogenicity.
[6-8]
 It is therefore desirable to engineer 
nanoparticles with high colloidal stability in biological fluids. Additionally, maximal surface 
accessibility for drug/gene loading and delivery is desirable.  
    Previously, we reported that layered double hydroxide (LDH) can effectively deliver 
drug/DNA into several types of cells including fibroblasts, HEK 293, CHO cells and 
neurons.
[9-11]
 LDH is a family of anionic clays, and can be found in nature and also readily 
synthesized in the laboratory.
[12, 13]
 Similar to hydrotalcite, the LDH composition can be 
expressed as the formula [M
2+
1–x M
3+
x(OH)2]
x+
(A
n–
)x/n•mH2O, where M
2+ 
represents a 
divalent metal cation, M
3+
 a trivalent metal cation, and A
n–
 an anion. The typical morphology 
of LDH nanoparticles is a hexagonal, plate-like, stacked layer structure, with a lateral 
diameter tailored from 50 to 300 nm.
[14]
 With the exchangeable property, the LDHs are able 
to load various negatively charged therapeutics, such as DNA and RNA, anionic drugs and 
peptide/proteins. Many investigations show that LDHs are a potential drug and gene delivery 
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candidate as they have many intrinsic advantages, including good biocompatibility, low 
cytotoxicity, high drug loading and controllable drug release mechanism.
[15-21]
 However, in 
vivo applications of these nanoparticles have been hampered by their tendency to aggregate 
in biological environments, resulting in inflammatory responses or death. Therefore, it is 
necessary to improve the stability of LDH nanoparticles for in vivo applications.  
    Several methods have been used to increase stability of colloidal systems, including 
surfactant molecule attachment on the nanoparticle surface, surface modification of 
functional groups and modification designed to enhance stability via steric repulsion and 
electrostatic repulsion.
[22]
 For example, silver nanoparticles were modified with two 
surfactants (sodium dodecyl sulfate and polyoxyethylenesorbitane monooleate-Tween 80) to 
improve anti-aggregation properties.
[23]
 PEGylation is an often used strategy to maintain 
colloidal stability via the steric effect.
[22, 24, 25]
  It is well-known that charged nanomaterials 
adsorb strongly on oppositely charged surfaces, and they are widely used to stabilize the 
nanoparticles.[26] Recently, we used BSA to coat LDH nanoparticles and found that these 
LDH-BSA complexes are colloidally stable in various electrolyte solutions.[27] Chemical 
crosslinking is one of the highly versatile methods to create a network on the nanoparticle 
surface by crosslinking functional groups of the surface molecules. Crosslinking with the 
amine-carboxylic acid, isocyanate-OH/NH2 reaction and Schiff base formation,
[28, 29] can 
prevent aggregation via steric repulsion. Dynamic light scattering (DLS) is a common 
method to study aggregation and colloid stability of various nanoparticles, which was thus 
used in this research.[30, 31] 
  
 
  
5 
 
 
Scheme 1. Schematic illustration of BSA-coating onto LDH nanoparticles and subsequent 
GTA crosslinking. 
It is ideal to design a well-dispersed colloidal system over a wide range of buffer 
conditions with ready redispersity, while simultaneously having surface accessibility for 
loading therapeutics. Our previous stabilization of LDH nanoparticles with BSA was 
achieved in specific buffer conditions (Step A in Scheme 1), but the BSA-LDH complexes 
became unstable at low concentrations. Moreover collected BSA-LDH particles are poorly 
redispersed in aqueous solution. Therefore, in this study, we crosslinked BSA after coating 
onto the LDH surface with glutaraldehyde (GTA) (Step B in Scheme 1) and demonstrated 
that this crosslinked BSA-LDH system has an enhanced colloidal stability and excellent 
redispersity. The optimized crosslinking only consumed a small portion of functional groups 
in BSA, leaving the majority available for further surface modification. Note that the 
crosslinked LDHs showed cytotoxicity similar to LDH alone, indicating their good 
biocompatibility for biomedical applications. 
   
2. Materials and Methods 
2.1 Materials 
Complementary strands of dsDNAs were purchased from GeneWorks and annealed at 75 °C 
for 10 min. One strand of the duplex was covalently coupled to the cy3 fluorophore at the 5′ 
end before annealing. Glutaraldehyde (GTA) solution (25%) was bought from Ajax 
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Finechem, and other chemicals and reagents from Sigma-Aldrich if not illustrated specifically. 
Water used in experiments was deionized Milli-Q water. 
 
2.2 Synthesis of LDH nanoparticles 
Mg2Al-Cl-LDH (pristine LDH) was prepared using a co-precipitation-hydrothermal treatment 
method, as reported previously.
[17, 32]
 In brief, LDH was synthesized by mixing 40 ml NaOH 
solution (0.15 M) with 10 ml salt solution containing MgCl2 (3.0 mmol) and AlCl3 (1.0 mmol) 
under vigorous stirring. The resultant precipitate was washed and then hydrothermally treated 
at 100 
o
C for 16 h, giving an LDH suspension with the mass concentration of 4.0 mg/ml. 
 
2.3 Crosslinking of BSA coated on LDH  
Two mililiters of 4 mg/ml LDH suspension was added into 2 ml of 10 mg/ml BSA solution 
(dissolved in deionized Milli-Q water) drop by drop under vigorously magnetic stirring for 30 
min to ensure saturated absorption. The BSA-coated LDH (BSA-LDH) nanoparticles were 
then added with GTA solution at a BSA:GTA molar ratio of 1:0.5, 1:15, 1:45, or 1:135, and 
incubated overnight to form crosslinked BSA-LDH (BSA-LDH-GTA).       
 
2.4 Quantification of active amino groups on crosslinked BSA 
GTA was applied as the crosslinking agent to react with BSA (as shown in Scheme 2). The 
determination of unreacted amino groups was performed using the reaction of TNBS (2, 4, 6-
trinitrobenzene sulfonic acid) with free amino groups. As a simulation, BSA (50.0 mg) was 
dissolved in 10.0 ml reaction buffer (0.1 M sodium bicarbonate, pH 8.5). Aliquots of 1.0, 2.5, 
5.0, 10.0, 20.0, 30.0, 60.0, 80.0 and 100.0 µl of 5% GTA solution were added gradually to 
1.0 ml BSA solution and the total volume was adjusted with the reaction buffer to a total 2.0 
ml. After 24 h incubation at 20 °C under constant shaking, 1.0 ml 0.01% TNBS solution was 
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added into the reaction mixture and shaken at 500 rpm for 2 h at 40 °C. The solution was then 
assayed by recording the absorbance at 343 nm.  The content of free amino groups on the 
crosslinked BSA surface was calculated in relation to BSA treated in the same manner as 
described above but without using GTA. 
 
 
 
 
Scheme 2. Schematic illustration of BSA reaction with GTA 
 
2.5 Colloidal stability test 
The size and polydispersity index (Pdi) of BSA-LDH and BSA-LDH-GTA at different 
concentrations (diluted for 0, 10, 160, and 320 times) were measured on a Nano Zetasizer 
(Nano ZS, MALVERN Instruments). The same volume of PBS was then mixed with BSA-
LDH or BSA-LDH-GTA under vigorous stirring for 30 min and the particle size distribution 
was monitored similarly. LDHs in water and in PBS were also measured for the particle size 
distribution on a Nano Zetasizer instrument. 
 
2.6 Redispersion ability test 
After centrifugation, BSA-LDH or BSA-LDH-GTA was collected and frozen in liquid 
nitrogen for 10 min, and then freeze-dried for 24 h, followed by being redispersed in water 
under gentle ultrasonication. The particle size distribution of water-redispersed particles 
(equilibrate to the original concentration) was measured and then compared with the initial 
one in the suspension.  
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2.7 Nucleic acid association with LDH 
The association of dsDNA with LDH was conducted by mixing dsDNA with pristine LDH, 
BSA-LDH, and BSA-LDH-GTA at the LDH: DNA mass ratio of 40:1 using light agitation at 
37 °C overnight.  
 
2.8 In vitro cytotoxicity test and cellular uptake 
Rat vascular smooth muscle cells (SMC) and human breast tumour cell line (MCF-7) were 
seeded in a 96-well or 6-well plate at a density of 4-5 × 10
4
 cells/cm
2
 in growth medium 
(Medium 199 and DMEM medium respectively, containing 10% foetal calf serum, 10 U/ml 
penicillin and 10 µg/ml streptomycin), and incubated at 37 °C in a humidified atmosphere 
with 5% CO2. 
    Cytotoxicity of BSA-LDH-GTA was examined by the MTT (Sigma) assay. Twenty-four 
hours after seeding, the cells were treated with growth medium containing BSA-LDH-GTA 
(LDH 10, 50, 100, 200 or 500 µg/ml). The control cells were treated with growth medium 
only. After 24, 48 and 72 h incubation, 20 μl of 5 mg/ml MTT (3-[4, 5-dimethylthiazol-2-yl]-
2, 5-diphenyl tetrazolium bromide) solution was added, and then incubated at 37 °C for 4 h. 
Culture medium was then removed, and formazan crystals within cells solubilized by 
incubation with 0.2 ml DMSO for 10 min. Absorbance was measured at 490 nm on a 
SpectraMax M5 microplate reader, and cell viability calculated as (absorbance in the 
treatment well)/(absorbance in the control well) × 100%.  
    Cell uptake efficacy of BSA-LDH and BSA-LDH-GTA was determined by flow cytometry 
(BD LSM II). Twenty-four hours after cell seeding, the cells were treated with growth 
medium containing BSA-LDH-dsDNA-cy3 or BSA-LDH-dsDNA-cy3-GTA for 24 h (both 
contained the same amount of dsDNA-cy3). After centrifugation and washing with PBS for 
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three times, the cells were fixed in 2% paraformaldehyde/PBS and analyzed on the flow 
cytometer.  
 
2.9 Characterization 
The particle size distribution and zeta potential of LDH, BSA-LDH, and BSA-LDH-GTA in 
aqueous solutions were measured on a Nano Zetasizer instrument. Transmission electron 
microscopy (TEM) images were obtained on a JEOL 1010A transmission electron 
microscope at an acceleration voltage of 100 kV. Powder X-ray diffraction (XRD) patterns 
were recorded on a Rigaku Miniflex X-ray Diffractometer using Co Kα source (λ = 0.178897 
nm) at a scanning rate of 0.02
o/s (2θ) from 2θ = 2o to 2θ = 80o. Fourier Transform Infrared 
(FTIR) spectra were recorded on a Nicolet 6700 spectrometer by accumulating 32 scans at a 
resolution of 4 cm
-1
 in the attenuated total reflection model.  
 
3. Results and Discussion 
3.1 BSA-coated LDH nanoparticles and redispersity 
As shown in Figure 1A and Figure S1, after hydrothermal treatment, a monodispersed LDH 
nanoparticle suspension was obtained with an average hydrodynamic diameter of 105 nm and 
a Pdi of 0.211, in agreement with the previous report.
[33]
 When the LDH suspension was 
added into electrolyte solution (e.g. PBS or culture medium), LDH nanoparticles formed 
aggregates with the average particle size being in the micrometer range (>1000 nm) in PBS 
(not shown) and 400 nm in culture medium (Figure 1A), respectively. Our previous work 
has successfully developed a BSA coating method to prevent aggregation of LDH 
nanoparticles in PBS or culture medium.
[27]
 As shown in Figure 1A, the particle size 
distribution of BSA-LDH (5:2) in PBS or culture medium was similar to that of BSA-LDH 
originally suspended in water. These phenomena showed that coating LDH with BSA was 
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able to prevent aggregation of LDH nanoparticles in electrolyte solutions. As we previously 
reported, the aggregation was probably due to the bridging effect of adsorbed serum 
molecules from the medium or reduced electrostatic repulsion caused by adsorption of ions 
on the LDH surface that counteracts the intrinsic surface charge of LDHs. We believe that 
BSA coating probably provides a strong steric repulsion and is able to prevent LDH particle 
aggregation in electrolyte solutions and the culture medium. 
 
                        
Figure 1. (A) Particle size distribution of LDH and BSA-LDH (5:2) in water, PBS or culture 
medium. Note: the size of LDH in PBS was over the measurement limit of Nanosizer and not 
  
11 
 
shown here; (B) Particle size distribution of redispersed BSA-LDH after freeze-drying. Each 
experiment was carried out in 3 independent experiments. 
Figure 1B shows the redispersion ability of BSA-LDH after centrifugation and freeze-
drying compared with the initial BSA-LDH suspension. The data revealed that the 
redispersed BSA-LDH had many large aggregates with the size > 1000 nm, different from 
that in BSA-LDH suspension (average particle size of 171 nm). The BSA-LDH suspension 
contains many free BSA molecules, which are in adsorption equilibrium with the BSA 
adsorbed on the LDH surface, thereby maintaining colloidal stability. Freeze-drying 
following centrifugation removes the free BSA from solution, preventing equilibrium being 
reached again during redispersion, resulting in incomplete dispersion. As freeze-drying 
techniques are an essential process in the manufacture pharmaceuticals, it is of great 
importance to enhance the redispersion ability of BSA-LDH complexes.   
3.2 Colloidal stability of BSA- coated LDH nanoparticles 
As shown in Figure 2, BSA-LDH (the BSA/LDH mass ratio = 5:2, the LDH concentration = 
2000 µg/ml) had an average size of 176 nm and a Pdi of 0.229. At this BSA/LDH mass ratio, 
there were about 0.7 mg of BSA adsorbed onto 1.0 mg of LDH and 3.6 mg of free BSA in 1.0 
ml aqueous suspension.
[27] 
When this BSA-LDH suspension was diluted 10 times (the LDH 
concentration = 200 µg/ml), the particle size distribution of BSA-LDH remained the same 
(the average size = 173 nm, and Pdi = 0.230). However, when the BSA-LDH suspension was 
continuously diluted, the particle average size increased to 298 nm (the LDH concentration = 
12.5 µg/ml) and then 864 nm (the LDH concentration = 6.3 µg/ml). This aggregation can be 
again explained by the disturbed equilibrium between BSA adsorbed on LDH and free BSA 
in solution after dilution. With the addition of water, the concentration of free BSA in 
solution decreases. For example, the concentration of free BSA was reduced from 3.6 mg/ml 
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to only 22.5 µg/ml in the suspension diluted for 160 times. Thus some adsorbed BSA desorbs 
from the surface to solution. As BSA desorption continues, LDH particles would share BSA 
molecules via the protein bridging effect, which leads to particle aggregation.      
 
  
Figure 2. Particle size distribution of BSA-LDH (mass ratio of BSA: LDH = 5:2) at different 
concentrations. Each experiment was carried out in 3 independent experiments. 
3.3 Enhanced colloidal stability by crosslinking BSA on the LDH surface 
We next employed a crosslinking strategy to increase BSA-LDH stability and redispersity. 
First, the effectiveness of crosslinking BSA by using GTA was examined. The amount of 
unreacted amino groups deceased significantly with increasing GTA amount used (Table 1 
and Figure S2), indicating that there was a progressive degree of crosslinking.
[34]
 After 
addition of 40 µl 5% GTA or more, very little change in the unreacted amino group number 
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was observed, indicating that all available amino groups had participated in the GTA 
crosslinking.  
 
Table 1 Free amino group in each BSA molecule after glutaraldehyde cross-linking  
5% Glutaraldehyde volume 
(µl) 
Amino groups per BSA molecule 
           Mean               S.D.                  
1                                                               37.24              1.30 
2.5                                                            34.93              0.58 
5                                                               33.04              1.42 
10                                                             18.76              0.31 
20                                                              6.09               0.57 
30                                                              2.51               0.52 
40                                                              1.77               1.29 
60                                                              1.79               0.72 
80                                                              2.01               0.53 
100                                                            1.71               1.43        
 
The number of amino groups on the crosslinked BSA was determined. GTA volumes of 1 to 100 µl for 
quantitative cross-linking of the 59 amino groups in the BSA molecules were employed in these tests.  
 
To determine the optimized GTA concentration for stabilizing the BSA-LDH nanohybrids, 
a series of BSA: GTA molar ratios (1:0.5, 1:15, 1:45, and 1:135) were used and the obtained 
suspensions were subjected to dilution tests. As shown in Figure 3A and Table S2, the 
average particle size of BSA-LDH-GTA was around 170 nm at the BSA/GTA ratio of 1:135 
when diluted from 40 to 640 times. In all other cases (BSA:GTA molar ratio = 1:0.5, 1:15 
and 1:45), the average particle size increased, indicating that some aggregation still took 
place even though the adsorbed BSA molecules were partly crosslinked. Therefore, the molar 
ratio of BSA: GTA (1:135) was applied in the following experiments. 
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  Figure 3. (A) The average particle size of BSA-LDH-GTA at different BSA: GTA molar 
ratios and dilution times; (B) The particle size distribution of BSA-LDH-GTA (the BSA: 
GTA molar ratio = 1:135) at different concentrations. Each experiment was carried out in 3 
independent experiments. 
        The particle size distribution of BSA-LDH-GTA (1:135) also remained the same after 
10-, 160- and 320-fold dilution (Figure 3B), in sharp contrast with that presented in Figure 2. 
This suggests that the crosslinking of surface adsorbed BSA by GTA can avoid/minimize the 
release of adsorbed BSA into solution, thus preventing LDH particles from aggregation 
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caused by dilution. Interestingly, the BSA: GTA molar ratio of 1:135 corresponded to 5 µl 5% 
GTA (Table 1), which means that there were 33 amino groups available per BSA molecule 
after crosslinking. Therefore, the optimized BSA/GTA molar ratio of 1:135 ensures sufficient 
colloidal stability of the LDH nanoparticle system, and at the same time maintains an 
adequate number of free amino groups/BSA for further modification and/or loading.  
 
 
Figure 4. The average particle size of BSA-LDH or BSA-LDH-GTA at different LDH 
concentrations in water and PBS. Each experiment was carried out in 3 independent 
experiments. 
    As shown in Figure 4 and Table S2, the average size of the initial BSA-LDH particles in 
water or PBS remained at about 175 nm when the suspension was diluted up to 80-fold, but 
increased dramatically when diluted 320-fold. In contrast, BSA-LDH-GTA nanohybrids 
remained the same size (around 180 nm) in both water and PBS when diluted. This stability 
can be attributed to the crosslinking of BSA, which immobilizes BSA onto the LDH surface 
and maintains the colloidal stability through steric repulsion. The comparison clearly 
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demonstrates the enhancement of BSA-LDH colloidal stability through the crosslinking 
strategy.  
3.4 Improved redispersity of BSA-LDH after crosslinking 
 
Figure 5. Particle size distribution of BSA-LDH-GTA and redispersed one. Each experiment 
was carried out in 3 independent experiments. 
As shown in Figure 5 and Table S1, the redispersity of freeze-dried BSA-LDH-GTA hybrids 
in water was obviously improved. After BSA-LDH-GTA hybrids were redispersed with 
gentle ultrasonication, the particle size distribution with an average particle size of 219 nm 
and a Pdi of 0.323 was very similar to that for the parent BSA-LDH-GTA hybrids. This 
redispersity is markedly better than that for un-crosslinked BSA-LDH (Figure 1B) under the 
same conditions.  The crosslinked BSA on the LDH surface was now immobilized with a 
more rigid configuration, which may keep the freeze-dried particles better separated. As a 
result, the BSA-LDH-GTA hybrids were more readily redispersed in water. This property is 
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of importance to the pharmaceutical sector, because freeze-drying technique is essential for 
the storage and transport of pharmaceuticals.  
 
3.5 Cytotoxicity of BSA-LDH-GTA  
 In general, the viability of cancer cell line, MCF-7, and smooth muscle cells (SMCs) after 
exposure to BSA-LDH-GTA (Figure 6A, B) gradually decreased with the increasing particle 
concentration and the incubation time.
[32]
 The viability of SMCs treated with 10-100 µg/ml of 
BSA-LDH-GTA hybrids did not change significantly after the first day of incubation, but 
decreased by 20 to 30% at day 2 to 3. In contrast, a significant reduction in cell viability was 
observed in BSA-LDH-GTA at the concentrations of 200-500 µg/ml of BSA-LDH-GTA at 
day 2-3.  
 BSA-LDH-GTA at 10-200 µg/ml did not affect the MCF-7 cell viability significantly 
during the 3-day incubation period (> 80%), while 500 µg/ml significantly reduced their 
viability after 2 to 3 days. Compared with LDH’s cytotoxicity reported previously (cell 
viability were over than 90% within 3 days incubation at the concentration range of 10-500 
µg/ml),
[35]
 BSA-LDH-GTA hybrids were slightly more toxic to SMCs, but still suggesting a 
good biocompability. The increased cytotoxicity is possibly due to the unreacted aldehyde 
groups in GTA that are known to induce some toxicity.
[36]
  
In most in vitro tests for drug and gene delivery,
[33, 37, 38]
 the LDH concentration is 
normally in the range of 10-100 µg/ml. Thus this toxicity test has demonstrated that the BSA-
LDH-GTA delivery platform has negligible toxicity for SMCs and the cancer cell line MCF-
7 in our in vitro assay. 
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Figure 6. Cell viability of SMCs (A) and MCF-7 (B) after treated with BSA-LDH-GTA 
(BSA: GTA molar ratio = 1:135) at concentrations from 0 to 500 µg/ml. Statistics; each 
experiment was carried out in duplicate and 3 independent experiments were performed. The 
data are presented as the mean ± SEM. One-way ANOVA with Bonferroni’s post-hoc test 
was used to assess statistical significance. * p < 0.05, ** p < 0.01, *** p < 0.001, **** 
p < 0.0001.   
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3.6 Cellular uptake 
 According to our previous report, a five-fold excess of LDH nanoparticles is sufficient to 
ensure maximum association of dsDNA with LDHs.
[26]
 The conditions required for the same 
amount of dsDNA intercalation were confirmed by gel electrophoresis (Figure S3). Therefore, 
the LDH:dsDNA mass ratio of 40:1 was used to ensure BSA-LDH and BSA-LDH-GTA to 
contain the same amount of dsDNA. 
                
Figure 7. Histogram showing (A) the percentage of SMCs cells internalizing BSA-LDH or 
BSA-LDH-GTA and (B) the percentage of MCF-7 cells internalizing BSA-LDH or BSA-
LDH-GTA monitored by flow cytometry. Statistics; each experiment was carried out in 
duplicate and 3 independent experiments were performed. The data are presented as the mean 
± SEM.  T-test was used to assess statistical significance. * p < 0.05, ** p < 0.01, *** p < 
0.001, **** p < 0.0001.   
 
    As shown in Figure 7, after 24 h incubation, the percentage of SMCs internalizing 
fluorescent BSA-LDH-dsDNA-cy3-GTA particles was about 67%, 30% lower than that for 
cells internalizing BSA-LDH-dsDNA-cy3 (96%). MCF-7 cells took up 17% less BSA-LDH-
dsDNA-cy3-GTA particles (68%) than BSA-LDH-dsDNA-cy3 (85%). The results indicate 
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that GTA crosslinking inhibits cell uptake to some degree compared to uncrosslinked 
nanoparticles. The possible reason is loss of functional positive amino groups on the surface 
of BSA-LDH nanoparticles after crosslinking. The positive charges on the particle surface 
increases cell surface affinity. As previously reported, increasing the amount of amine groups 
facilitates cellular uptake of nanoparticles by various cell lines.
[39]
 Although BSA-LDH-GTA 
showed slight inhibition to cell uptake compared to BSA-LDH, the GTA crosslinking 
strategy provides much higher colloidal stability and much easier redispersity of LDH 
nanoparticles for more potential bioapplications in vivo. 
It should be mentioned that the loaded dsDNA could be released via the anion exchange 
with the cytosol anions or through dissolution of LDH in the endosome/lysosome, as 
proposed previously.
[38]
 
 
 
4. Conclusions 
Size control of LDH nanoparticles is a challenging problem for clinical applications. This 
work introduced a crosslinking strategy to stabilize LDH nanoparticles based on the previous 
BSA coating strategy, and crosslinked BSA-LDH hybrids had improved colloidal stability 
and redispersity of freeze-dried samples. Although the cytotoxicity of BSA-LDH-GTA 
increased especially at the concentration of 500 µg/ml when compared to LDH cytotoxicity, 
BSA-LDH-GTA at concentrations of 10-200 µg/ml had minimal effect. Importantly, our 
modified LDH nanoparticles can be further conjugated with functional molecules to promote 
target delivery to specific cells types. Overall, this new crosslinking strategy promises a more 
stable BSA coated LDH nanoparticles system with broad applications in vitro and in vivo. 
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The BSA coated and crosslinked LDH (BSA-LDH-GTA) nanoparticles have shown 
enhanced colloidal stability and excellent redispersity in comparison with uncrosslinked 
BSA-LDH and pristine LDH nanoparticles.  
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Highlights 
    Crosslinking optimization of BSA coated on LDH surface is achieved. 
    Crosslinked LDH hybrids have a higher colloidal stability in electrolyte solutions. 
    Crosslinked LDH hybrids are more readily redispersed in aqueous solution. 
    Crosslinked LDH hybrids have a low cytotoxic. 
    Crosslinked LDH hybrids are also efficiently taken up by cells. 
 
